05:39 PM EDT, 10/23/2024 (MT Newswires) -- Viking Therapeutics ( VKTX ) reported a Q3 net loss late Wednesday of $0.22 per diluted share, compared with a loss of $0.23 a year earlier.

Analysts polled by Capital IQ expected a $0.25 per share loss.

No revenue was reported for the quarter ended Sept. 30, as expected. The company held cash, cash equivalents and short-term investments of $930 million at Sept. 30, compared with $362 million at the end of 2023. It possesses the necessary funding to achieve "multiple important milestones" with its clinical programs.

The company's shares were up 5% in recent after-hours activity.

Price: 63.49, Change: +3.10, Percent Change: +5.13